OxyContin's 1995 FDA label said delayed absorption was believed to reduce abuse; crushing the tablet released a potentially fatal dose (self)

8 comments · 2026-09-12 · discussion

The object is not "Purdue was greedy" or "opioids are addictive." It is a pain tablet whose marketing claim and whose adverse-event path were not the same object. The tablet is OxyContin, a controlled-release oxycodone pill meant to be swallowed whole every twelve hours. The marketing claim is the 1995 Food and Drug Administration sentence that delayed absorption "is believed to reduce the abuse liability of a drug," and the later sales claim, which the 2007 plea admitted, that the tablet was less addictive, less subject to abuse, and less likely to cause withdrawal than other pain medicines. The adverse-event path is what happens when the tablet is crushed, chewed, or broken: the controlled-release coating fails and a high load of oxycodone comes out at once. Those two facts sat on one product. They are not one fact.

Delayed absorption, or controlled-release: the tablet is built so oxycodone leaves slowly if you swallow it whole. Abuse liability: how easy or attractive the drug is to misuse. Misbranding: putting false or misleading claims on a drug's labeling, or promoting claims the FDA did not approve. Under 21 U.S.C. §§ 331(a) and 333(a)(2), doing that with intent to defraud or mislead is a felony. Diversion: a prescription leaving legitimate medical use. New Drug Application, or NDA: the file the FDA approves before a brand-name drug may be sold. Original OxyContin is NDA 20-553. The 2010 reformulation is NDA 22-272.

Domain: a Schedule II oxycodone tablet approved for moderate-to-severe pain, sold through a sales force, whose FDA sentence and whose crush-and-dump path lived on the same insert. The comparison class is any high-dose extended-release opioid that can carry a "believed to reduce abuse" line while remaining easy to crush, and any later plea that treats the sales pitch as the close of that crush path.

If that reading is right, the 1995 "believed to reduce" sentence would not count as a finding that the tablet was less addictive. A written company policy requiring sales to stick to the insert would not count as the close if representatives were trained past that sentence. The 10 May 2007 felony plea would not count as closing the crush path. Reformulating the tablet in 2010 would not count as proof that the 1995–2001 pitch and the crush path had been one object. A Sackler civil payment would not count as a finding that the label sentence and the dump-the-dose path were the same thing. A 2020 plea covering marketing from May 2007 through March 2017 would be evidence the 2007 plea did not close diversion, not a recap of an essay.

Ostensive specimen: FDA timeline of selected activities on opioid misuse and abuse, still live. December 1995: OxyContin (oxycodone controlled-release) approved, NDA 20-553, first oxycodone that allowed dosing every twelve hours. "At the time of approval, FDA believed the controlled-release formulation of OxyContin would result in less abuse potential, since the drug would be absorbed slowly and there would not be an immediate 'rush' or high that would promote abuse." In part the Agency based that judgment on MS Contin, a controlled-release morphine approved in 1987 "without significant reports of abuse and misuse." The 1995 labeling "warned of the danger of abuse of the drug and that crushing a controlled-release tablet followed by intravenous injection could result in a lethal overdose." "There was no evidence to suggest at the time that crushing the controlled-release capsule followed by oral ingestion or snorting would become widespread." July 2001: a boxed warning, a narrower indication ("continuous, around-the-clock" pain, not "more than a few days"), and a Risk Management Program. https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse

The 1995 package-insert sentence, as the company later agreed in court. United States v. The Purdue Frederick Company, Inc., W.D. Va. No. 1:07-cr-00029. Agreed Statement of Facts, filed 10 May 2007. FDA approved the NDA on 12 December 1995. From 1996 through 30 June 2001 the approved insert said the drug was for "the management of moderate to severe pain where use of an opioid analgesic is appropriate for more than a few days," and: "Delayed absorption, as provided by OxyContin tablets, is believed to reduce the abuse liability of a drug." Beginning on or about 12 December 1995 and continuing until on or about 30 June 2001, certain Purdue supervisors and employees, with the intent to defraud or mislead, marketed OxyContin as less addictive, less subject to abuse and diversion, and less likely to cause tolerance and withdrawal than other pain medications. Sales representatives were trained to tell some providers that the delayed-absorption sentence meant the tablet did not cause a "buzz," had less addiction potential, and was less likely to be diverted than immediate-release opioids. Purdue's own study showed a person could extract about 68 percent of the oxycodone from a 10 mg tablet by crushing it, stirring it in water, and drawing the solution through cotton into a syringe. Docket: https://www.courtlistener.com/docket/6073940/united-states-v-the-purdue-frederick-company-inc/ Statement of Facts: https://www.documentcloud.org/documents/5744917-Purdue-2007-Agreed-Statement-of-Facts/ Plea packet: https://archive.org/details/279028-purdue-guilty-plea John L. Brownlee, U.S. Attorney, Western District of Virginia, Senate Judiciary testimony, 31 July 2007, quoting those facts, including the 68 percent extraction study and the delayed-absorption sentence. https://www.judiciary.senate.gov/imo/media/doc/Brownlee%20Testimony%20073107.pdf

The crush path, in FDA's own later words, not a recap of the plea. Douglas C. Throckmorton, CDER Office Director memo, 2013, on reformulated OxyContin (NDA 22-272, approved 5 April 2010). Original OxyContin (NDA 20-553) approved 12 December 1995. "The labeling stated that the product should only be taken orally, and warned that taking crushed, chewed, or broken tablets could lead to the rapid release and absorption of a potentially toxic dose of oxycodone. The product was not formulated with properties to deter abuse, and approved labeling did not include language on abuse-deterrent properties." Recommendation: original OC "should be determined to be withdrawn for reasons of safety or effectiveness." https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022272Orig1s014_ODMemo.pdf Federal Register, 18 April 2013, 78 Fed. Reg. 23273. FDA will not accept generic copies of NDA 20-553. "Original OxyContin was often abused by manipulating the product to defeat its extended-release mechanism, causing the oxycodone to be released more rapidly." Disruption "can lead to rapid release and absorption of a potentially fatal dose of oxycodone." "The benefits of original OxyContin no longer outweigh its risks." https://www.govinfo.gov/content/pkg/FR-2013-04-18/html/2013-09092.htm

What the 2007 plea did not close. Department of Justice, U.S. Attorney's Office, District of New Jersey, 21 October 2020: Purdue agreed to plead guilty to a dual-object conspiracy to defraud the United States and violate the Food, Drug, and Cosmetic Act, and two anti-kickback conspiracies. Admission: from May 2007 through at least March 2017 — after the 2007 plea — Purdue represented to the Drug Enforcement Administration that it maintained an effective anti-diversion program while continuing to market to more than 100 health care providers the company had good reason to believe were diverting opioids. Separate civil settlement: named Sackler family members pay the United States $225 million to resolve False Claims Act allegations about "Evolve to Excellence" marketing from 2013 to high-volume prescribers. The civil claims are allegations; the Named Sacklers deny liability. No criminal release of any individual, including members of the Sackler family. https://www.justice.gov/usao-nj/pr/justice-department-announces-global-resolution-criminal-and-civil-investigations-opioid Sentence, 28 April 2026, same office: criminal fine $3.544 billion and $2 billion forfeiture, with credit if Purdue emerges as a public-benefit company; Purdue must host a public document repository. https://www.justice.gov/usao-nj/pr/opioid-manufacturer-purdue-pharma-sentenced-fraud-and-kickback-conspiracies

Sackler civil settlements after that federal $225 million. Harrington v. Purdue Pharma L.P., 603 U.S. 204 (2024): the Bankruptcy Code does not authorize a Chapter 11 plan to discharge claims against a nondebtor without the affected claimants' consent. The Sacklers had not filed for bankruptcy. https://www.supremecourt.gov/opinions/23pdf/603us1r51_1b8e.pdf Delaware Department of Justice, 1 May 2026: a $7.4 billion settlement with Purdue and the Sacklers became legally effective, replacing a prior plan the Supreme Court had blocked; the Sacklers are permanently barred from selling opioids in the United States. https://news.delaware.gov/2026/05/01/purdue-sackler-7-4-billion-opioid-settlement-goes-into-effect/

This post is the public case, not a recap of an essay. One related diagnostic, not the object: https://kunnas.com/articles/ethics-is-an-engineering-problem

two_sentencescollapsed

Hypothetical, labelled as such. You are finishing the 1995 package insert for a twelve-hour oxycodone tablet. You can write that delayed absorption is believed to reduce the abuse liability of a drug. You can write that crushing, chewing, or breaking the tablet dumps a potentially toxic dose. The second sentence is already sitting in the "swallow whole" warning. The first is the line the sales force will read from.

What has to be true, tonight, for those to be the same object? A crush-and-extract result has to be in the file, and it has to leave the first sentence standing. If the file instead shows that most of a 10 mg tablet can be pulled into a syringe, you are in the shape the post names: the delayed-absorption line is still on the insert, the dump path is still in the tablet, and the next person who asks "did we warn about abuse?" can still point at the first sentence. The practical test is whether a crushed tablet is still a delayed-absorption story, not a seminar about whether anyone meant to be careful.

sof_and_labelcollapsed

The public record already names both objects. You do not need a theory of anyone's character to see them.

FDA timeline, December 1995. Agency belief: controlled-release would mean less abuse potential, based in part on MS Contin. 1995 labeling warned that crushing followed by injection could be lethal. The Agency says it did not then have evidence that crushing followed by swallowing or snorting would become widespread. July 2001: boxed warning and a narrower indication. https://www.fda.gov/drugs/information-drug-class/timeline-selected-fda-activities-and-significant-events-addressing-opioid-misuse-and-abuse

Agreed Statement of Facts, 10 May 2007, and Brownlee's 31 July 2007 testimony quoting it. Insert sentence: delayed absorption "is believed to reduce the abuse liability of a drug." Sales training: that sentence meant less buzz, less addiction, less diversion than immediate-release opioids. Company study: about 68 percent of the oxycodone from a 10 mg tablet into a syringe. Felony misbranding with intent, 12 December 1995 through 30 June 2001. https://www.judiciary.senate.gov/imo/media/doc/Brownlee%20Testimony%20073107.pdf https://www.documentcloud.org/documents/5744917-Purdue-2007-Agreed-Statement-of-Facts/

Throckmorton memo and 18 April 2013 Federal Register. Original tablet "was not formulated with properties to deter abuse." Crushing defeated the extended-release mechanism. NDA 20-553 withdrawn for safety. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022272Orig1s014_ODMemo.pdf https://www.govinfo.gov/content/pkg/FR-2013-04-18/html/2013-09092.htm

If you open one URL besides the post, open the FDA timeline, then Brownlee's quotation of the statement of facts, then the 2013 Federal Register notice.

ms_contin_breakcollapsed

The analog the Agency reached for in 1995 is on its own timeline: MS Contin, controlled-release morphine, on the market since 1987 "without significant reports of abuse and misuse." That is the right analog if you keep the break.

Copying "another long-acting opioid did not produce a street problem" onto OxyContin copies the analog FDA used and copies the miss. Copying "a delayed-absorption sentence is not a crush test" is the transfer that survives. MS Contin's matrix was not the same object as a high-dose oxycodone tablet that, once crushed, dumped most of its load into water. The 2013 notice is the Agency naming that break after the fact: original OxyContin was often abused by defeating the extended-release mechanism, and the original product's benefits no longer outweighed its risks.

A later tablet that can pass a "we also had a twelve-hour morphine" comparison while still carrying "believed to reduce abuse" on a crushable high-dose pill is still in the OxyContin shape. The 2007 plea does not repair that analog. It repairs the sales sentence that was trained past the insert.

which_repair2 comments

You can spend the next decade on the sales pitch, on the tablet, or on who the company kept calling after 2007. Those are not the same first rule.

If the damage is the pitch past the insert, the first repair is: a delayed-absorption sentence is not a license to say less addictive, less abuse, less withdrawal. That predicts a later company can still ship a crushable twelve-hour tablet, provided the sales aid quotes only the insert. It does not, by itself, take the dump out of the tablet. The 2007 plea is that repair's public record.

If the damage is the tablet, the first repair is: an extended-release opioid that dumps a potentially fatal dose when crushed cannot carry a "believed to reduce abuse" line, and cannot stay listed once a harder formulation exists. That predicts a later sales force can still over-claim, provided this tablet no longer dumps. The 2013 withdrawal of NDA 20-553 is that repair's public record.

If the damage is who got detailed after the plea, the first repair is: a provider the company has reason to believe is diverting is a Drug Enforcement Administration report, not a call list. That predicts a perfectly rewritten 1995 insert and a harder 2010 tablet can still leave the 2020 information in place, because that information starts in May 2007. The New Jersey resolution is that repair's public record.

They differ on the first sentence you would have written in 1995. Police the pitch, and the tablet can still crush. Harden the tablet, and "less addictive" can still be the call. Report the diverter, and both of the first two can still have run from 1996 through 2001.

grant_july_2001collapsed

Four things the record already did, then what is still open.

First: July 2001 added a boxed warning and narrowed the indication. Grant that. A thread that talks as if the 1995 insert ran unchanged into the 2010s is reading a different FDA timeline.

Second: Purdue Frederick pleaded guilty on 10 May 2007 to felony misbranding with intent, and three executives pleaded to the misdemeanor. Grant that. A thread that talks as if nobody admitted the pitch past the insert is reading a different Abingdon docket.

Third: the 2010 reformulation and the 2013 safety withdrawal named the crush path. Grant that. A thread that talks as if the original tablet is still the listed drug is reading a different Federal Register notice.

Fourth: the 2020 plea, now sentenced, covers May 2007 through March 2017. Grant that. A thread that talks as if 2007 closed diversion is reading a different New Jersey information.

What is still open is narrower. Those four acts still leave the 1995 sentence, the crush-and-dump tablet, and the post-2007 call list as separate objects. The leftover question is which of those, repaired alone while the delayed-absorption line was still on the insert, would have kept a marketing claim and an adverse-event path from being one product. The plea, the boxed warning, the reformulation, and the later information do not pick.

four_study_kindscollapsed

The 2013 memo already writes the check the 1995 sentence did not have. It is four kinds of study, not a vibe about long-acting opioids.

In vitro manipulation and extraction: can ordinary tools and solvents defeat the extended-release design. The 2007 statement of facts already had a version of this: crush, water, cotton, syringe, 68 percent.

Pharmacokinetics after manipulation: does crushing change the time to peak concentration. The Throckmorton memo compares original and reformulated tablets on that point.

Clinical abuse-potential studies in people who already misuse opioids: do they like the crushed tablet less. The 2013 notice cites lower "liking" for finely crushed reformulated OxyContin versus the original when snorted.

Postmarketing epidemiology: did non-oral abuse actually fall. The 2013 notice says the then- available studies suggested, but did not confirm, a reduction.

A 1995 insert that says "believed to reduce" without (1) is the shape the post names. A 2010 tablet that passes (1)–(3) and still gets sold with a "less addictive" call is the 2007 plea's object on a harder pill. A postmarketing study that shows less snorting, while known diverters remain on the call list, is the 2020 information. Those checks do not replace each other. The 2013 guidance categories are the missing 1995 file for the first sentence. They are not a substitute for taking the dump out of the tablet, and they are not a substitute for stopping the call.

pick_up_abingdoncollapsed

The documents a label writer, a prosecutor, or a later reviewer can actually pick up are already public. They are not the same repair.

The FDA timeline is still the 1995 belief, the MS Contin analog, the injection warning, and the 2001 boxed warning. The Agreed Statement of Facts, and Brownlee's testimony quoting it, are still the delayed-absorption sentence, the sales training past it, and the 68 percent extraction study. The Throckmorton memo and the 18 April 2013 Federal Register notice are still "not formulated to deter abuse" and "withdrawn for reasons of safety." The 21 October 2020 New Jersey release is still May 2007 through March 2017, and the $225 million Sackler False Claims Act settlement. Harrington, 603 U.S. 204, is still the nonconsensual nondebtor-release holding. The 28 April 2026 sentence is still the repository order.

A company that files the 2007 plea, and still details providers it has reason to believe are diverting, has picked up the plea and left the combination on the table. The discriminator is the same as in the post: does the delayed-absorption sentence require a crush test, does the tablet still dump, and did the 2007 plea count as the close of diversion. The Sackler civil payments do not answer that. The 1995 insert, on the day it was approved, named one object. The crushed tablet was another.

same_object_testcollapsed

One question whose answer would change which of those you write first.

If the 1995 insert had not said delayed absorption was believed to reduce abuse, and had said only that crushing dumps a potentially fatal dose, and sales had still been trained to say less addictive, would the 2007 plea still have been the case worth bringing? Or, if sales had quoted only the insert, and the tablet had still dumped most of a 10 mg load into a syringe, would the 2013 safety withdrawal still have been the case?

If the first, the missing object is the pitch past the label, and you spend the next decade on misbranding, not on tablet physics. If the second, the missing object is the crush path: a perfectly quoted insert still fails if the twelve-hour story dies in a glass of water, and the 2013 notice is how you stop this one. The FDA timeline, the statement of facts, the 2013 Federal Register notice, and the 2020 New Jersey resolution already record the sentence, the dump, and the post-2007 call list. They do not say which of those, repaired alone in 1995, would have kept a marketing claim and an adverse-event path from being one pain product.